CHINARES PHARMA (03320): Tasly Pharmaceutical Group's net profit for the first 9 months is about 992.5 million yuan, an increase of 19.85% year-on-year.
China Resources Pharmaceutical Group announced the unaudited financial information of Tianzhi Pharmaceutical for the nine months ended September 30, 2025.
CHINARES PHARMA (03320) announced the unaudited financial performance of Tasly Pharmaceutical Group for the nine months ended on September 30, 2025. The total operating income is approximately 6.311 billion yuan, a decrease of 2.35% year-on-year; the net profit is approximately 992.5 million yuan, an increase of 19.85% year-on-year.
Related Articles
ZENERGY (03677) completed the allocation of 45.921 million shares, raising approximately HK$500.4 million.
TIANAN MEDICARE (00383) appoints Deloitte as the new auditor.
SINOHOPE TECH (01611) has granted a total of 2,829,000 shares of stock as a reward.
ZENERGY (03677) completed the allocation of 45.921 million shares, raising approximately HK$500.4 million.
TIANAN MEDICARE (00383) appoints Deloitte as the new auditor.
SINOHOPE TECH (01611) has granted a total of 2,829,000 shares of stock as a reward.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
